Skip to main content
. 2019 Dec 11;2019:1825849. doi: 10.1155/2019/1825849

Table 1.

Clinical and biochemical characteristics of the study subjects.

Healthy control lgAVN lgAV without nephritis p
Subjects, n 76 43 66
Demographics
Age 7.88 ± 3.024 9.42 ± 4.32 8.79 ± 4.04 >0.05
Gender (male/female) 44/32 26/17 37/29 >0.05
Lipid profiles
TG (mmol/L) 2.75 (1.12-3.39)b 1.26 (0.8-1.66)a 1.08 (0.67-1.87)a <0.05
TC (mmol/L) 0.84 (0.59-2.99)b 3.93 (3.44-4.56)a 3.98 (3.19-4.85)a <0.05
HDL-C (mmol/L) 1.23 (1.05-1.37) 1.21 (1-1.36) 1.29 (1.03-1.55) >0.05
LDL-C (mmol/L) 1.9 (1.5-2.16)b 2.21 (1.77-2.75)a 2.1 (1.57-2.78)a <0.05
apoA (g/L) 1.06 (0.99-1.15)b 0.9 (0.75-1.04)a 0.93 (0.78-1.06)a <0.05
apoB (g/L) 0.57 (0.47-0.66) 0.58 (0.49-0.7) 0.58 (0.45-0.72) >0.05
apoM (mg/L) 18.17 (15.83-20.22)a 23.92 (21.25-26.1)b 25.96 (23.50-27.46)c <0.05
Kidney biochemical profiles
BUN (μmol/L) 3.8 (3.25-4.47) 4.02 (2.86-5.5) 4.09 (2.99-4.95) >0.05
CRE (μmol/L) 30.9 (24.23-36.4)a 41.1 (36-53)b 35.55 (30.75-42.43)c <0.05
UA (g/L) 230.05 (181.93-269.63)a 265 (218.6-330.3)b 223.3 (187.13-281.55)a <0.05
hs-CRP (mg/L) / 1.94 (1.02-3.87) 3.74 (1.37-12.1) <0.05
Immunoglobulins
lgG (g/L) / 8.4 (6.16-11) 9.97 (8.29-11.7) <0.05
lgM (g/L) / 2 (154-2.35) 2.2 (1.52-3.19) >0.05
lgA (g/L) / 1.25 (0.84-1.42) 1.05 (0.87-1.56) >0.05
lgE (g/L) / 150.8 (59.09-447.3) 275.05 (119.38-298.63) >0.05
Complements
C3 (g/L) / 0.95 (0.8-1.13) 1 (0.9-1.15) >0.05
C4 (g/L) / 0.18 (0.15-0.23) 0.23 (0.18-0.28) <0.05

abc means not sharing a common superscript are significantly different among the healthy controls, lgAVN, and lgAV without nephritis groups at p < 0.05. Data are presented as median (range). TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; apoA1: apolipoprotein A1; apoB: apolipoprotein B; apoM: apolipoprotein M.